In the past 12 hours, coverage was dominated by education and public-facing science-adjacent items, alongside a handful of research and policy/industry updates. Jharkhand Academic Council (JAC) released its Class 12 results and topper lists, reporting stream-wise pass percentages (Arts 96.14%, Commerce 93.37%, Science 82.92%) and naming top scorers across Science, Commerce, and Arts. Separately, the CDC downplayed public risk from hantavirus aboard the M/V Hondius, saying the “risk to the American public is extremely low” while urging passengers to follow guidance as evacuation was expected to begin May 11. Other “how-to” health coverage included a review suggesting yoga, Tai Chi, and walking/jogging can improve sleep quality similarly to medication/therapy (with fewer side effects), and a separate piece on walking misconceptions and step-count targets.
Several science and technology stories also stood out in the last 12 hours. A cosmology report described a large Chinese-led supercomputer simulation (“HyperMillennium”) that “fast-forward[s]” the universe from the Big Bang to the present using 4.2 trillion virtual dark matter particles over 13.8 billion years. In physics instrumentation, researchers reported an ultra-sensitive pressure sensor that measures pressure from individual particle impacts using a laser-held silica sphere, with potential applications including detecting elusive particles like those that could make up dark matter. Space exploration coverage focused on how NASA’s VIPER rover could support future Artemis lunar south-pole objectives, including mapping near-surface water ice for in-situ resource utilization.
On the biomedical and biotech front, the most concrete developments were corporate/clinical announcements rather than new clinical findings. Catalyst Pharmaceuticals announced a settlement of FIRDAPSE® (amifampridine) patent litigation with Hetero Labs, including a commitment not to market a generic in the U.S. earlier than January 2035 (if approved). Angelini Pharma also announced an agreement to acquire Catalyst for about $4.1 billion, positioning the deal as an entry into the U.S. market and consolidation in brain health and rare disease. In parallel, Pharming Group reported CIS conference presentations tied to leniolisib in pediatric APDS and expanded access in CVID/CVID-like disorders, and Zealand Pharma detailed the execution framework for a share buy-back program.
Looking beyond the last 12 hours, the broader week shows continuity in themes—health risk communication (hantavirus), education outcomes (multiple board-result items), and ongoing research narratives (e.g., AI-assisted science, climate/ocean impacts, and quantum/space topics). However, the evidence for any single “major event” in the scientific sense is limited in the most recent window; the strongest corroborated “big” items are the JAC result release (multiple related headlines) and the set of major biotech corporate actions (Catalyst/Angelini and FIRDAPSE settlement), while many other headlines appear to be standalone announcements or general-interest science explainers.